<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Reduced-intensity conditioning (RIC) umbilical cord blood (UCB) transplantation is increasingly used in hematopoietic stem cell transplantation (HCT) for older and medically unfit patients </plain></SENT>
<SENT sid="1" pm="."><plain>Data on the efficacy of HCT after RIC relative to myeloablative conditioning (MAC) are limited </plain></SENT>
<SENT sid="2" pm="."><plain>We compared the outcomes of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) patients &gt;18 yrs who received UCB grafts after either RIC or MAC </plain></SENT>
<SENT sid="3" pm="."><plain>One hundred nineteen adult patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in complete remission (CR) underwent an UCB transplant after RIC (n =74, 62%) or MAC (n = 45, 38%) between January 2001 and December 2009 </plain></SENT>
<SENT sid="4" pm="."><plain>Conditioning was either reduced intensity and consisted of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 50 mg/kg, fludarabine 200 mg/m(2), and total-body irradiation (TBI) 200 cGy or myelablative and consisted for <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 120 mg/kg, fludarabine 75 mg/m(2), and TBI 1200-1320 cGy </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (day -3 to day +180) and <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil (day -3 to day +45) post-HCT immunosuppression and hematopoietic growth factor </plain></SENT>
<SENT sid="6" pm="."><plain>Use of RIC was reserved for patients &gt;45 years (n = 66, 89%) or preexisting severe comorbidities (n = 8, 11%) </plain></SENT>
<SENT sid="7" pm="."><plain>The 2 groups were similar except for preceding <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (RIC = 28% versus MAC = 4%, P &lt; .01) and age that was dictated by the treatment protocols (median, RIC = 55 years versus MAC = 33years; P &lt; .01) </plain></SENT>
<SENT sid="8" pm="."><plain>The incidence of neutrophil recovery at day +42 was higher with RIC (94% versus MAC = 82%, P &lt; .1), whereas platelet recovery at the sixth month was similar (RIC = 68% versus MAC = 67%, P = .30) </plain></SENT>
<SENT sid="9" pm="."><plain>Incidence of grade II-IV <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (aGVHD) (RIC = 47% versus MAC = 67%, P &lt; .01) was decreased with similar incidence of <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD (cGVHD) (RIC = 30% versus MAC = 34%, P = .43) </plain></SENT>
<SENT sid="10" pm="."><plain>Median follow-up for survivors was 3.8 and 4.5 years for RIC and MAC, respectively (P = .4) </plain></SENT>
<SENT sid="11" pm="."><plain>Using RIC, 3-year <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e>) was decreased (31% versus MAC = 55%, P = .02) and 3-year relapse incidence was increased (43% versus MAC = 9%, P &lt; .01) </plain></SENT>
<SENT sid="12" pm="."><plain>Two-year transplant-related mortality (TRM) was similar (RIC = 19% versus MAC = 27%; P = .55) </plain></SENT>
<SENT sid="13" pm="."><plain>In multivariate analysis, RIC recipients and those in CR2 with CR1 duration &lt;1 year had higher risk of relapse and poorer <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> with no independent predictors of TRM </plain></SENT>
<SENT sid="14" pm="."><plain>UCB with RIC extends the use of allogeneic HCT for older and frail patients without excessive TRM with greater benefit for patients in CR1 and CR2 with longer CR1 </plain></SENT>
</text></document>